Remove Accountant Remove Pharmaceutical Remove Securities
article thumbnail

E200: Buying or Selling a Small Business? Get the Insider Tips You Need to Secure Your Deal

How2Exit

Get the Insider Tips You Need to Secure Your Deal - Watch Here rn rn About the Guest(s): rn Patrick O'Connell is an experienced mergers and acquisitions (M&A) advisor with a profound depth of knowledge in buying and selling small businesses valued between one to $20 million.

Business 130
article thumbnail

PODCAST REVIEW: ACQUIRING MINDS: How to Buy the Business Where You Work | Corey Veverka Interview

How2Exit

b' rn How2Exit Sponsor: rn rn Reconciled provides industry-leading virtual bookkeeping and accounting services for busy business owners and entrepreneurs across the US. rn About The Guest(s): Corey Veverka is the owner of TBS, a company that specializes in validation and compliance for pharmaceutical manufacturing facilities.

Business 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Artificial intelligence: is it good or bad for society?

Growth Business

Whether it is JPMorgan’s AI cashflow model that claims to cut manual banking work by 90 per cent, AI therapists or AI-powered security cameras, AI is making its mark on society and the workplace. In many ways, this is a good thing that will help the pharmaceutical industry detect and understand disease.

IT 52
article thumbnail

Learning Old Lessons From Recent Life Sciences Earnout Disputes: Above All Else, Words Matter

Cooley M&A

Alexion Pharmaceuticals (Del. J&J’s efforts were required to be consistent with its “usual practices” for a “priority medical device,” and J&J was prohibited from taking into account the cost of milestone payments in making any commercially reasonable development decisions. In both Fortis v. Johnson & Johnson (Del.

article thumbnail

Spot Cyber & IT Challenges Through Improved Due Diligence

M&A Leadership Council

Also, I find it’s helpful to remind deal leaders and business sponsors that every organization has a different definition of what is traditionally called IT, for example, core platform, shared services, network, infrastructure, applications, data, security, etc. All businesses need to be digital businesses these days.

IT 52
article thumbnail

Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024

Cooley M&A

While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. Why did life sciences outperform the market? The last quarter of the year ended with a surge of deal activity.

M&A 52
article thumbnail

Spot Cyber & IT Challenges

M&A Leadership Council

Also, I find it’s helpful to remind deal leaders and business sponsors that every organization has a different definition of what is traditionally called IT, for example, core platform, shared services, network, infrastructure, applications, data, security, etc. All businesses need to be digital businesses these days.

IT 52